Wnt Pathway Activators Counteract Thalidomide Teratogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Thalidomide induces teratogenic effects by causing oxidative stress, leading to enhanced Bmp signaling, up-regulation of Dkk1, and inhibition of canonical Wnt/β-catenin signaling, resulting in cell death and birth defects in embryonic limb and eye development.
Innovation Solution
A pharmaceutical composition comprising an anti-neoplastic agent and an anti-teratogenic agent that activates the Wnt signaling pathway downstream of the Wnt ligand-receptor interaction, using inhibitors such as Noggin, anti-Dkk1 antibody, LiCl, or GSK3β inhibitors to block Bmp/Dkk1/Wnt signaling, thereby counteracting thalidomide-induced teratogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thalidomide is administered to treat neoplastic conditions, then anti-neoplastic effect is achieved, but teratogenic effects occur causing birth defects
Solution Approach 1:
The patent introduces Wnt pathway activators as intermediary substances that mediate between thalidomide treatment and embryonic development protection. These activators bind to Frizzled receptors or interact with β-catenin to activate Wnt signaling, creating a protective intermediary mechanism that counteracts thalidomide's teratogenic effects without interfering with its anti-neoplastic activity
Solution Approach 2:
The patent applies preliminary anti-action by administering Wnt pathway activators before or concurrently with thalidomide to pre-establish protective signaling. This preliminary activation of Wnt/β-catenin signaling creates a protective state in embryonic cells before thalidomide exposure, preventing the oxidative stress and apoptosis that would otherwise occur
2Reliability
If thalidomide induces oxidative stress to achieve anti-neoplastic effect, then cell death in cancer cells occurs, but cell death in embryonic cells occurs causing limb defects
Solution Approach 1:
The patent applies local quality by targeting Wnt pathway activation specifically to embryonic tissues where it is needed for protection, while allowing thalidomide to exert its oxidative stress effects in neoplastic tissues. The Wnt activators create a localized protective environment in developing embryos without interfering with thalidomide's systemic anti-cancer effects
3Reliability
If Dkk1 is up-regulated to inhibit Wnt signaling in response to Bmp activation, then Bmp signaling is enhanced, but teratogenic effects are amplified
Solution Approach 1:
The patent applies inversion by reversing the normal Dkk1-mediated inhibition of Wnt signaling. Instead of allowing Dkk1 to block Wnt pathway activation, the patent uses Wnt pathway activators that override Dkk1 inhibition, effectively inverting the regulatory relationship to ensure Wnt signaling remains active despite elevated Dkk1 levels from Bmp activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these inhibitors significantly reduces thalidomide-induced cell death and birth defects by modulating Bmp/Dkk1/Wnt signaling, demonstrating a method to inhibit the teratogenic effects of thalidomide and potentially other anti-neoplastic agents.
Implementation Method 1
Thalidomide induces oxidative stress through the formation of free radical-initiated reactive oxygen species (ROS) in limb bud cells and embryos of thalidomide-sensitive rabbits
Implementation Method 2
GSH is oxidized to glutathione disulfide in the detoxification processes, which leads to a shift in the intracellular redox potential
Data Source
AI summary
Pharmaceutical compositions comprising anti-teratogenic agents are disclosed. Additionally, pharmaceutical compositions comprising anti-neoplastic agents and anti-teratogenic agents are disclosed. Methods of assessing the teratogenicity of a compound are disclosed. The present invention further comprises applications of the aforementioned compositions and methods.